Heijtink R A, Kruining J, Bakker M, Schalm S W
Antiviral Res. 1985;Suppl 1:273-9. doi: 10.1016/s0166-3542(85)80038-3.
Thirty-one individuals (health care workers) were vaccinated with recombinant hepatitis B vaccine (10 microgram dose) and their immune response (anti-HBs) was compared to that of twenty-five health care workers after vaccination with plasma-derived vaccine (20 microgram dose). Although the seroconversion rate and the percentage of anti-HBs/a antibodies at month 7 were comparable, the geometric mean titre of anti-HBs at month 7 was considerably lower for the recombinant vaccine group (857.4 vs. 6736.5 IU/l). However, vaccinees from the two groups showing seroconversion at month 1 had comparable titres at month 7. Raising the dose of HBsAg in the recombinant vaccine may favourably influence the seroconversion rate at month 1 and thereby the immune response after three injections.
31名个体（医护人员）接种了重组乙肝疫苗（剂量为10微克），并将他们的免疫反应（抗-HBs）与25名接种血浆源性疫苗（剂量为20微克）的医护人员的免疫反应进行了比较。尽管第7个月时的血清转化率和抗-HBs/a抗体百分比相当，但重组疫苗组第7个月时抗-HBs的几何平均滴度显著较低（857.4对6736.5 IU/l）。然而，两组在第1个月出现血清转化的接种者在第7个月时滴度相当。提高重组疫苗中HBsAg的剂量可能会对第1个月时的血清转化率产生有利影响，从而对三次注射后的免疫反应产生有利影响。
